E-Newsletter - February 2018

ABStracts from 2018 meetings 

Genitourinary cancers symposium february 8-10

Alliance researchers presented the following abstract during the 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care held in San Francisco, CA. The symposium explored the latest science and its clinical application, and featured keynote lectures from world-renowned experts on the most clinically relevant research across the spectrum of GU cancers, along with abstracts with novel and emerging data. Co-sponsors of the symposium included the American Society of Clinical Oncology, American Society for Radiation Oncology and Society of Urologic Oncology.

-- Alliance A031203: Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial
Lead author: Daniel J. George, MD | more about the trial.

Gastrointestinal cancers symposium january 18-20

Alliance researchers presented three abstracts during the 2018 Gastrointestinal Cancers Symposium held in San Francisco, CA. The symposium featured multidisciplinary topics of international interest, covering cancers of the esophagus and stomach, pancreas, small bowel and hepatobiliary tract, and the colon, rectum and anus. Co co-sponsored by the American Gastroenterological Association Institute, American Society of Clinical Oncology, American Society for Radiation Oncology and Society of Surgical Oncology.
-- Pilot Study: A Pilot Case Control Study: Could a Gastric Cancer Risk Screening Tool Help Identify High Risk Patients for Endoscopic Screening in the US?
Lead author: Haejin In, MD

-- CALGB (Alliance) 80405: Association of RAS Mutations with Race in Metastatic Colorectal Cancer CALGB 80405 (Alliance)
Lead author: Amikar Sehdev, MD, MPH | more about the trial

-- NCCTG (Alliance) N0147: Immunoscore  Provides Prognostic Information in Low (T1-3N1) and High Risk (T4 or N2) Subsets of Stage III Colon Carcinoma Patients Treated with Adjuvant FOLFOX in a Phase III Trial (NCCTG N0147; Alliance)
Lead author: Frank A. Sinicrope, MD | more about the trial


For other articles in this issue of the Alliance E-News newsletter, see below.